transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2016-3-3-59-66transmed-190Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHИмплантация окклюдера ушка левого предсердия для профилактики системных эмболий. Первый опыт в СевероЗападном регионеLeft atrial appendage occluder implantation for prevention of systemic embolism. First experience in the north-west regionОсадчийАндрей МихайловичOsadchyAndrey M.an_osadchy@mail.ruАгарковМаксим ВасильевичAgarkovMaxim V.noemail@neicon.ruВласенкоСергей ВасильевичVlasenkoSergey V.noemail@neicon.ruСтовпюкОксана ФедоровнаStovpyukOksana F.noemail@neicon.ruПавловаНаталья ЕвгеньевнаPavlovaNatalia E.noemail@neicon.ruМамаеваОльга ПетровнаMamaevaOlga P.noemail@neicon.ruМиллерЮлия ВитальевнаMillerJulia V.noemail@neicon.ruКаменевАлександр ВалентиновичKamenevAlexander V.noemail@neicon.ruГуреевСергей ВикторовичGureevSergey V.noemail@neicon.ruЛебедеваЛебедева СветланаLebedevaDmitriy S.noemail@neicon.ruЩербакСергей ГригорьевичShcherbakSergey G.noemail@neicon.ruЛебедевДмитрий СергеевичLebedevDmitriy S.noemail@neicon.ruСпбГБУЗ ГБ № 40РоссияCity Hospital № 40Russian FederationФГБУ «СЗФМИЦ им. В.А. Алмазова»РоссияFederal Almazov Medical Research CentreRussian FederationСпбГБУЗ № 40РоссияCity Hospital № 40Russian FederationСЗФМИЦ им. В.А. АлмазоваРоссияFederal Almazov Medical Research CentreRussian FederationФГБУ «СЗФМИЦ им. В.А. Алмазова»РоссияFederal Almazov Medical Researh CentreRussian FederationСпбГБУЗ ГБ № 40РоссияFederal Almazov North-West Medical Research CentreRussian FederationСпбГБУЗ ГБ № 40РоссияHead of City Hospital № 40Russian FederationФГБУ «СЗФМИЦ им. В.А. Алмазова» Минздрава РоссииРоссияFederal Almazov North-West Medical Research CentreRussian Federation201623122016335966Copyright © Осадчий А.М., Агарков М.В., Власенко С.В., Стовпюк О.Ф., Павлова Н.Е., Мамаева О.П., Миллер Ю.В., Каменев А.В., Гуреев С.В., Лебедева Л.С., Щербак С.Г., Лебедев Д.С., 20162016Осадчий А.М., Агарков М.В., Власенко С.В., Стовпюк О.Ф., Павлова Н.Е., Мамаева О.П., Миллер Ю.В., Каменев А.В., Гуреев С.В., Лебедева Л.С., Щербак С.Г., Лебедев Д.С.Osadchy A.M., Agarkov M.V., Vlasenko S.V., Stovpyuk O.F., Pavlova N.E., Mamaeva O.P., Miller J.V., Kamenev A.V., Gureev S.V., Lebedeva D.S., Shcherbak S.G., Lebedev D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/190

Впервые представляются случаи успешной имплантации различных окклюдеров в ушко левого предсердия в Северо-Западном регионе РФ с целью профилактики системных тромбоэмболий. Имплантация окклюдеров достаточно безопасная и эффективная процедура, позволяющая отменить постоянный прием пероральных антикоагулянтов. Имплантация окклюдера может быть альтернативой при высоком риске кровотечений и ограничениях постоянной антикоагулянтной терапии.

The first experience of various LAA occluders implantation in the North-West region for prevention of systemic thromboembolic events is reported. The implantation procedure is considered to be rather safety and effective and provides an opportunity for subsequent oral anticoagulants withdrawal. Therefore LAA occluder implantation can be an alternative in patients with high risk of bleeding and contraindications for permanent anticoagulation.

фибрилляция предсердийинсультушко левого предсердияантикоагулянтыимплантация окклюдераatrial fibrillationstrokeleft atrial appendageanticoagulantsoccluder implantationReferencesGo A.S., et al. Heart Disease and Stroke Statistics-2014 Update. Circulation. 2014; 128: 00-00Go A.S., et al. Heart Disease and Stroke Statistics-2014 Update. Circulation. 2014; 128: 00-00Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373: 155-166.Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373: 155-166.Zateyschikov D.A., Zotova I.V., Dankovtseva E.N. et al. Thrombotic events and antithrombotic therapy for arrhythmias. M.: Practice, 2011. p. 264. In Russian [Затейщиков Д.А., Зотова И.В., Данковцева Е.Н., Сидоренко Б.А. Тромбозы и антитромботическая терапия при аритмиях. М.: Практика, 2011. c. 264]Zateyschikov D.A., Zotova I.V., Dankovtseva E.N. et al. Thrombotic events and antithrombotic therapy for arrhythmias. M.: Practice, 2011. p. 264. In Russian [Затейщиков Д.А., Зотова И.В., Данковцева Е.Н., Сидоренко Б.А. Тромбозы и антитромботическая терапия при аритмиях. М.: Практика, 2011. c. 264]Marini C., De Santis F., Sacco S., et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36: 1115-1119.Marini C., De Santis F., Sacco S., et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36: 1115-1119.Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263-272.Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263-272.Lip G.Y., Frison L., Halperin J.L. et all. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED score. J Am CollCardiol. 2011; 173-180.Lip G.Y., Frison L., Halperin J.L. et all. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED score. J Am CollCardiol. 2011; 173-180.Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with nonvalvular atrial fibrillation: a systematic review and metaanalysis. ThrombRes. 2006;118: 321-333.Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with nonvalvular atrial fibrillation: a systematic review and metaanalysis. ThrombRes. 2006;118: 321-333.Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med. 2007; 146(12): 857-867.Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med. 2007; 146(12): 857-867.Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151.Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151.Patel M.R., Mahaffey K.W., Gard J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-891.Patel M.R., Mahaffey K.W., Gard J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-891.Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-992.Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-992.Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84(2): 527-539.Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84(2): 527-539.Reddy V.Y., Holmes D., Doshi S.K., et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123: 417-424.Reddy V.Y., Holmes D., Doshi S.K., et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123: 417-424.Reddy V.Y., Doshi S.K., Sievert H., et al. PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013; 127(6): 720-729.Reddy V.Y., Doshi S.K., Sievert H., et al. PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013; 127(6): 720-729.Holmes D.R.Jr., Kar S., Price M.J., et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J AmCollCardiol. 2014; 64(1): 1-12.Holmes D.R.Jr., Kar S., Price M.J., et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J AmCollCardiol. 2014; 64(1): 1-12.Meier B., Blaauw Y., Khattab A.A. et all. EHRA/ EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2014; 10: 1109-1125.Meier B., Blaauw Y., Khattab A.A. et all. EHRA/ EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2014; 10: 1109-1125.Boersma L., Schmidt B., Betts T. et all. EWOLUTION: design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. Catheter Cardiovasc Interv. 2016; in press.Boersma L., Schmidt B., Betts T. et all. EWOLUTION: design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. Catheter Cardiovasc Interv. 2016; in press.Holmes D.R. Jr., Kar S., Price M.J. et all. Prospective randomized evaluation of the WATCHMAN left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J AmCollCardiol. 2014; 64: 1-12.Holmes D.R. Jr., Kar S., Price M.J. et all. Prospective randomized evaluation of the WATCHMAN left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J AmCollCardiol. 2014; 64: 1-12.Tzikas A., Shakir S., Gafoor S., Omran H., Berti S., Santoro G., Kefer J., Landmesser U., Nielsen-Kudsk J.E., Cruz-Gonzalez I., Sievert H., Tichelbäcker T., Kanagaratnam P., Nietlispach F., Aminian A., Kasch F., Freixa X., Danna P., Rezzaghi M., Vermeersch P., Stock F., Stolcova M., Costa M., Ibrahim R., Schillinger W., Meier B., Park J.W. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016; 11(10): 1170-1179.Tzikas A., Shakir S., Gafoor S., Omran H., Berti S., Santoro G., Kefer J., Landmesser U., Nielsen-Kudsk J.E., Cruz-Gonzalez I., Sievert H., Tichelbäcker T., Kanagaratnam P., Nietlispach F., Aminian A., Kasch F., Freixa X., Danna P., Rezzaghi M., Vermeersch P., Stock F., Stolcova M., Costa M., Ibrahim R., Schillinger W., Meier B., Park J.W. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016; 11(10): 1170-1179.Mikhaylov E.N., Lebedev D.S., Gureev S.V. et al. Safety of combination of indirect and direct anticoagulants during catheter ablation of atrial fibrillation: a study on a large group of patients. Journal of arrhythmology. 2008; 53: 21-26. In Russian [Михайлов Е.Н., Лебедев Д.С., Гуреев С.В. и др. Безопасность одновременного применения непрямых и прямых антикоагулянтов при катетерной аблации фибрилляции предсердий: исследование на большой группе пациентов. Вестник аритмологии. 2008; 53: 21-26.]Mikhaylov E.N., Lebedev D.S., Gureev S.V. et al. Safety of combination of indirect and direct anticoagulants during catheter ablation of atrial fibrillation: a study on a large group of patients. Journal of arrhythmology. 2008; 53: 21-26. In Russian [Михайлов Е.Н., Лебедев Д.С., Гуреев С.В. и др. Безопасность одновременного применения непрямых и прямых антикоагулянтов при катетерной аблации фибрилляции предсердий: исследование на большой группе пациентов. Вестник аритмологии. 2008; 53: 21-26.]

The authors declare that there are no conflicts of interest present.